# Synedgen, Inc.

Canonical: https://abierto.us/vendors/synedgen-inc-hx79bd6yq521

- UEI: HX79BD6YQ521
- CAGE: 5JGC8
- Location: Claremont, CA
- Awards in window: 2 (7 transactions), $21,126,078 obligated, September 19, 2024 to September 26, 2025

## Awarding agencies

- Office of Assistant Secretary for Preparedness and Response: 1 awards, $18,828,663
- Defense Health Agency: 1 awards, $2,297,415

## Industries

- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology): $21,126,078

## Competition

- Full and Open Competition: 1 awards
- Full and Open Competition After Exclusion of Sources: 1 awards

## Largest awards

- 75A50124C00047 (definitive contract): $18,828,663, Barda - Aspr / Daappo / Barda DCMA. Advance the Development of Paag17g (Drug Product: Miist305), a Once Daily, Orally Administered, Gut-Restricted Drug, to Reduce Mortality and Morbidity Arising from Acute Exposure to Ionizing Radiation, Specifically Gastrointestinal (Gi) Injury (Gi-Ar. https://www.usaspending.gov/award/CONT_AWD_75A50124C00047_7505_-NONE-_-NONE-/
- HT942524C0049 (definitive contract): $2,297,415, Army Med Res Acq Activity. SBIR Phase III Proposal No. JW230017 Titled, "optimized, Field-Stable Glycopolymer-Mimicking Polysaccharide to Prevent Morbidity and Mortality in Exposure to Ionizing Radiation or Nuclear Injury". https://www.usaspending.gov/award/CONT_AWD_HT942524C0049_9700_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/synedgen-inc-hx79bd6yq521.